← Leaderboards
Reisa A. Sperling
Banner Health
$149,869,513
Attributed
$379,859,645
Total exposure
31
Grants
22
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $54.3M · FY2005–25$100M$75M$50M$25M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$420,358,426 · 32
By mechanism
R01$181,977,597 · 7
U24$167,922,818 · 1
P01$46,291,669 · 8
U19$19,700,703 · 1
P50$2,283,546 · 3
K24$1,354,447 · 1
Top collaborators
- Paul S. Aisen43 shared
- Keith A. Johnson36 shared
- Ronald C Petersen13 shared
- Jeffrey L. Cummings6 shared
- Jessica Brooke Langbaum5 shared
- Eric M Reiman5 shared
- Robert C Alexander3 shared
- Pierre N. Tariot2 shared
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposS DiseaseAmyloidPositron-Emission TomographyPre-ClinicalImpaired CognitionTau ProteinsPathologyImageCognitiveFundingParticipantUnited States National Institutes Of HealthMagnetic Resonance ImagingResearch PersonnelBrainClinical TrialsPrevention TrialMemoryAmyloid Beta-ProteinReportingNeuroimagingBiological MarkersDementia
Grant awards (139)
Alzheimer's Clinical Trials Consortium (ACTC)$29,438,964
U24 · FY2025 · AG
The Ante-Amyloid Treatment of Alzheimer's disease (A3) Trial and Alzheimer Plasma EXtension (APEX) Study$6,467,513
R01 · FY2025 · AG · contact PI
API A4 Alzheimer's Prevention Trial$4,136,602
R01 · FY2025 · AG
Impact of Amyloid and Tau on the Aging Brain: The Harvard Aging Brain Study$3,556,723
P01 · FY2025 · AG · contact PI
Detection of early cognitive change: Linking to clinically meaningful outcomes (Project 4)$266,967
P01 · FY2025 · AG · contact PI
Core A: Administrative Core$266,374
P01 · FY2025 · AG · contact PI
Alzheimer's Clinical Trials Consortium (ACTC)$28,436,169
U24 · FY2024 · AG
Combination anti-amyloid therapy for preclinical Alzheimer's disease$8,720,510
R01 · FY2024 · AG
API A4 Alzheimer's Prevention Trial$6,538,660
R01 · FY2024 · AG
Impact of Amyloid and Tau on the Aging Brain: The Harvard Aging Brain Study$3,629,309
P01 · FY2024 · AG · contact PI
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Open-Label Extension Study$2,608,673
R01 · FY2024 · AG · contact PI
Detection of early cognitive change: Linking to clinically meaningful outcomes (Project 4)$274,931
P01 · FY2024 · AG · contact PI
Core A: Administrative Core$274,317
P01 · FY2024 · AG · contact PI
Alzheimer's Clinical Trials Consortium (ACTC)$28,125,414
U24 · FY2023 · AG
Combination anti-amyloid therapy for preclinical Alzheimer's disease$8,723,068
R01 · FY2023 · AG
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Open-Label Extension Study$6,941,600
R01 · FY2023 · AG · contact PI
The A3 Study: Ante-Amyloid Prevention of Alzheimer's disease$3,979,320
R01 · FY2023 · AG · contact PI
Impact of Amyloid and Tau on the Aging Brain: The Harvard Aging Brain Study$3,491,054
P01 · FY2023 · AG · contact PI
The A3 Study: Ante-Amyloid Prevention of Alzheimer's disease$328,079
R01 · FY2023 · AG · contact PI
Detection of early cognitive change: Linking to clinically meaningful outcomes (Project 4)$274,931
P01 · FY2023 · AG · contact PI
Core A: Administrative Core$270,958
P01 · FY2023 · AG · contact PI
Alzheimer's Clinical Trials Consortium (ACTC)$16,738,113
U24 · FY2022 · AG
Combination anti-amyloid therapy for preclinical Alzheimer's disease$8,727,018
R01 · FY2022 · AG
API A4 Alzheimer's Prevention Trial$8,413,794
R01 · FY2022 · AG
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Open-Label Extension Study$6,943,250
R01 · FY2022 · AG · contact PI
Global Alzheimer's Platform Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease$4,856,514
R01 · FY2022 · AG
The A3 Study: Ante-Amyloid Prevention of Alzheimer's disease$4,308,552
R01 · FY2022 · AG · contact PI
Impact of Amyloid and Tau on the Aging Brain: The Harvard Aging Brain Study$3,455,408
P01 · FY2022 · AG · contact PI
The A3 Study: Ante-Amyloid Prevention of Alzheimer's disease$341,233
R01 · FY2022 · AG · contact PI
Detection of early cognitive change: Linking to clinically meaningful outcomes (Project 4)$285,829
P01 · FY2022 · AG · contact PI
Core A: Administrative Core$271,672
P01 · FY2022 · AG · contact PI
Alzheimer's Clinical Trials Consortium (ACTC)$16,802,375
U24 · FY2021 · AG
Global Alzheimer's Platform Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease$9,769,679
R01 · FY2021 · AG
Combination anti-amyloid therapy for preclinical Alzheimer's disease$8,732,454
R01 · FY2021 · AG
API A4 Alzheimer's Prevention Trial$7,162,340
R01 · FY2021 · AG
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Open-Label Extension Study$6,944,873
R01 · FY2021 · AG · contact PI
The A3 Study: Ante-Amyloid Prevention of Alzheimer's disease$3,980,365
R01 · FY2021 · AG · contact PI
Alzheimer's Clinical Trials Consortium (ACTC)$230,541
U24 · FY2021 · AG
Alzheimer's Clinical Trials Consortium (ACTC)$16,584,274
U24 · FY2020 · AG
Global Alzheimer's Platform Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease$9,845,298
R01 · FY2020 · AG
Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease$4,929,565
R01 · FY2020 · AG
Impact of Amyloid and Tau on the Aging Brain: The Harvard Aging Brain Study$3,308,596
P01 · FY2020 · AG · contact PI
Alzheimer's Clinical Trials Consortium (ACTC)$311,154
U24 · FY2020 · AG
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Open-Label Extension Study$295,100
R01 · FY2020 · AG · contact PI
Core A: Administrative Core$255,837
P01 · FY2020 · AG · contact PI
Detection of early cognitive change: Linking to clinically meaningful outcomes (Project 4)$254,520
P01 · FY2020 · AG · contact PI
Mentoring Imaging Research in Early AD$130,749
K24 · FY2020 · AG · contact PI
Alzheimer's Clinical Trials Consortium (ACTC)$13,976,431
U24 · FY2019 · AG
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Open-Label Extension Study$7,047,943
R01 · FY2019 · AG · contact PI
The A3 Study: Ante-Amyloid Prevention of Alzheimer's disease$3,981,411
R01 · FY2019 · AG · contact PI
Impact of Amyloid and Tau on the Aging Brain: The Harvard Aging Brain Study$2,689,773
P01 · FY2019 · AG · contact PI
Alzheimers Clinical Trials Consortium (ACTC)$2,251,991
U24 · FY2019 · AG
Core A: Administrative Core$623,209
P01 · FY2019 · AG · contact PI
Alzheimer's Clinical Trials Consortium (ACTC)$344,272
U24 · FY2019 · AG
Project 4: Amyloid and Tau Mediated Alterations in Memory Function and Cognitive Decline$287,188
P01 · FY2019 · AG · contact PI
Mentoring Imaging Research in Early AD$130,749
K24 · FY2019 · AG · contact PI
Alzheimer's Clinical Trials Consortium (ACTC)$14,053,120
U24 · FY2018 · AG
Combination anti-amyloid therapy for preclinical Alzheimer's disease$9,021,816
R01 · FY2018 · AG
API A4 Alzheimer's Prevention Trial$5,670,134
R01 · FY2018 · AG
Global Alzheimer's Platform Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease$4,967,947
R01 · FY2018 · AG
Impact of Amyloid and Tau on the Aging Brain: The Harvard Aging Brain Study$2,234,180
P01 · FY2018 · AG · contact PI
The Alzheimer's Clinical Trial Consortium - Down Syndrome Network (ACTC- DSN)$630,000
U24 · FY2018 · AG
Impact of Amyloid and Tau on the Aging Brain: The Harvard Aging Brain Study$356,123
P01 · FY2018 · AG · contact PI
Impact of Amyloid and Tau on the Aging Brain: The Harvard Aging Brain Study$224,361
P01 · FY2018 · AG · contact PI
Project 4: Amyloid and Tau Mediated Alterations in Memory Function and Cognitive Decline$220,943
P01 · FY2018 · AG · contact PI
Core F - Neuroimaging Core$176,004
P50 · FY2018 · AG · contact PI
Core A: Administrative Core$165,793
P01 · FY2018 · AG · contact PI
Core E - Outreach, Recruitment and Education Core$161,043
P50 · FY2018 · AG · contact PI
Mentoring Imaging Research in Early AD$132,369
K24 · FY2018 · AG · contact PI
Global Alzheimer's Platform Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease$5,001,194
R01 · FY2017 · AG
ANTI-AMYLOID TREATMENT IN ASYMPTOMATIC ALZHEIMERS DISEASE$2,688,971
U19 · FY2017 · AG · contact PI
Impact of Amyloid and Tau on the Aging Brain: The Harvard Aging Brain Study$2,411,664
P01 · FY2017 · AG · contact PI
Project 4: Amyloid and Tau Mediated Alterations in Memory Function and Cognitive Decline$244,304
P01 · FY2017 · AG · contact PI
Core A: Administrative Core$182,254
P01 · FY2017 · AG · contact PI
Core E - Outreach, Recruitment and Education Core$171,505
P50 · FY2017 · AG · contact PI
Mentoring Imaging Research in Early AD$132,369
K24 · FY2017 · AG · contact PI
The A3 Study: Ante-Amyloid Prevention of Alzheimer's disease$4,020,661
R01 · FY2016 · AG · contact PI
ANTI-AMYLOID TREATMENT IN ASYMPTOMATIC ALZHEIMERS DISEASE$3,286,257
U19 · FY2016 · AG · contact PI
Impact of Amyloid and Tau on the Aging Brain: The Harvard Aging Brain Study$2,275,025
P01 · FY2016 · AG · contact PI
Evolution of memory related fMRI activation over the course of MCI and AD$687,064
R01 · FY2016 · AG · contact PI
Project 4: Amyloid and Tau Mediated Alterations in Memory Function and Cognitive Decline$235,890
P01 · FY2016 · AG · contact PI
Core F - Neuroimaging Core$175,930
P50 · FY2016 · AG · contact PI
Core E - Outreach, Recruitment and Education Core$160,974
P50 · FY2016 · AG · contact PI
Core A: Administrative Core$160,021
P01 · FY2016 · AG · contact PI
Impact of Amyloid and Tau on the Aging Brain: The Harvard Aging Brain Study$138,510
P01 · FY2016 · AG · contact PI
Mentoring Imaging Research in Early AD$132,369
K24 · FY2016 · AG · contact PI
ANTI-AMYLOID TREATMENT IN ASYMPTOMATIC ALZHEIMERS DISEASE$3,987,763
U19 · FY2015 · AG · contact PI
Impact of Amyloid and Tau on the Aging Brain: The Harvard Aging Brain Study$2,345,103
P01 · FY2015 · AG · contact PI
Evolution of memory related fMRI activation over the course of MCI and AD$666,452
R01 · FY2015 · AG · contact PI
Project 4: Amyloid and Tau Mediated Alterations in Memory Function and Cognitive Decline$290,735
P01 · FY2015 · AG · contact PI
Core F - Neuroimaging Core$170,652
P50 · FY2015 · AG · contact PI
Core A: Administrative Core$160,021
P01 · FY2015 · AG · contact PI
Core E - Outreach, Recruitment and Education Core$156,145
P50 · FY2015 · AG · contact PI
ANTI-AMYLOID TREATMENT IN ASYMPTOMATIC ALZHEIMERS DISEASE$5,116,455
U19 · FY2014 · AG · contact PI
Impact of Amyloid on the Aging Brain$2,052,876
P01 · FY2014 · AG · contact PI
Evolution of memory related fMRI activation over the course of MCI and AD$686,405
R01 · FY2014 · AG · contact PI
Core F - Neuroimaging Core$175,930
P50 · FY2014 · AG · contact PI
Core E - Outreach, Recruitment and Education Core$160,974
P50 · FY2014 · AG · contact PI
Mentoring Imaging Research in Early AD$139,579
K24 · FY2014 · AG · contact PI
ANTI-AMYLOID TREATMENT IN ASYMPTOMATIC ALZHEIMERS DISEASE$4,621,257
U19 · FY2013 · AG · contact PI
Impact of Amyloid on the Aging Brain$1,958,622
P01 · FY2013 · AG · contact PI
Evolution of memory related fMRI activation over the course of MCI and AD$653,300
R01 · FY2013 · AG · contact PI
IMPLICATIONS OF AMYLOID DEPOSITION IN CLINICALLY NORMAL OLDER INDIVIDUALS$145,071
P50 · FY2013 · AG · contact PI
Mentoring Imaging Research in Early AD$139,579
K24 · FY2013 · AG · contact PI
Impact of Amyloid on the Aging Brain$2,087,652
P01 · FY2012 · AG · contact PI
Evolution of memory related fMRI activation over the course of MCI and AD$725,116
R01 · FY2012 · AG · contact PI
IMPLICATIONS OF AMYLOID DEPOSITION IN CLINICALLY NORMAL OLDER INDIVIDUALS$166,780
P50 · FY2012 · AG · contact PI
Mentoring Imaging Research in Early AD$139,579
K24 · FY2012 · AG · contact PI
Impact of Amyloid on the Aging Brain$2,108,435
P01 · FY2011 · AG · contact PI
IMPLICATIONS OF AMYLOID DEPOSITION IN CLINICALLY NORMAL OLDER INDIVIDUALS$154,150
P50 · FY2011 · AG · contact PI
Mentoring Imaging Research in Early AD$139,579
K24 · FY2011 · AG · contact PI
Impact of Amyloid on the Aging Brain$2,175,367
P01 · FY2010 · AG · contact PI
Evolution of memory-related fMRI activation over the course of MCI and AD$1,170,742
R01 · FY2010 · AG · contact PI
IMPLICATIONS OF AMYLOID DEPOSITION IN CLINICALLY NORMAL OLDER INDIVIDUALS$156,588
P50 · FY2010 · AG · contact PI
Mentoring Imaging Research in Early AD$137,526
K24 · FY2010 · AG · contact PI
Evolution of memory-related fMRI activation over the course of MCI and AD$1,158,759
R01 · FY2009 · AG · contact PI
IMPLICATIONS OF AMYLOID DEPOSITION IN CLINICALLY NORMAL OLDER INDIVIDUALS$151,800
P50 · FY2009 · AG · contact PI
Evolution of memory-related fMRI activation over the course of MCI and AD$1,171,848
R01 · FY2008 · AG · contact PI
ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE (ADNI)$3,648
M01 · FY2008 · RR · contact PI
TRIAL OF SIMVASTATIN TO SLOW THE PROGRESSION OF ALZHEIMER'S DISEASE$182
M01 · FY2008 · RR · contact PI
Evolution of memory-related fMRI activation over the course of MCI and AD$584,273
R01 · FY2007 · AG · contact PI
Evolution of memory-related fMRI activation over the course of MCI and AD$450,357
R01 · FY2007 · AG · contact PI
ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE (ADNI)$24,448
M01 · FY2007 · RR · contact PI
TRIAL OF SIMVASTATIN TO SLOW THE PROGRESSION OF ALZHEIMER'S DISEASE$1,223
M01 · FY2007 · RR · contact PI
Evolution of memory-related fMRI activation over the course of MCI and AD$618,115
R01 · FY2006 · AG · contact PI
FUNCTIONAL MAGNETIC RESONANCE IMAGING (fMRI)$326,701
P01 · FY2006 · AG · contact PI
TRIAL OF SIMVASTATION TO SLOW THE PROGRESSION OF ALZHEIMER'S DISEASE$3,297
M01 · FY2006 · RR · contact PI
REDUCING HOMOCYSTEINE TO SLOW COGNITIVE DECLINE IN ALZHEIMER'S DISEASE$2,748
M01 · FY2006 · RR · contact PI
REDUCING HOMOCYSTEINE TO SLOW COGNITIVE DECLINE IN ALZHEIMER'S$7,592
M01 · FY2005 · RR
TRIAL OF SIMVASTATIN TO SLOW THE PROGRESSION OF ALZHEIMER'S DISEASE$6,698
M01 · FY2005 · RR
ASSESSMENT MEASURES FOR ALZHEIMER'S DISEASE: PRIMARY PREVENTION TRIALS$446
M01 · FY2005 · RR
FACE-NAME ASSOCIATION: FMRI STUDIES IN AGING &MILD AD$159,981
K23 · FY2004 · NS
Trial of Simvastatin to Slow Progression of Alzheimer's$17,089
M01 · FY2004 · RR
Efficacy and Safety of LY451395 in Probable Alzheimer's$2,629
M01 · FY2004 · RR
FACE-NAME ASSOCIATION: FMRI STUDIES IN AGING &MILD AD$158,437
K23 · FY2003 · NS
FUNCTIONAL MAGNETIC RESONANCE IMAGING (fMRI)$199,493
P01 · FY2002 · AG
FACE-NAME ASSOCIATION: FMRI STUDIES IN AGING &MILD AD$153,890
K23 · FY2002 · NS
FACE-NAME ASSOCIATION: FMRI STUDIES IN AGING &MILD AD$143,197
K23 · FY2001 · NS
FACE-NAME ASSOCIATION: FMRI STUDIES IN AGING &MILD AD$142,141
K23 · FY2000 · NS